Bret Holley

Oppenheimer & Co analysts Bret Holley, Matthew Lowe, Job Taylor and Brian Abrahams maintained their Outperform rating for shares of ArQule Inc (Nasdaq: ARQL), with a price target of $11 per share. The analysts said that they expect ArQule Inc to initiate a ph.III trial of '197+Tarceva in non-...

Oppenheimer & Co. analysts Brian Abrahams, Bret Holley, Anupam Rama and Ryan Tochihara maintained their Perform rating for shares of Genzyme Corporation (Nasdaq: GENZ). The analysts said that Genzyme Corporation released the terms of a consent decree with the FDA that was inline with an earlier...